BiotechTube
Terns Pharmaceuticals

Terns Pharmaceuticals

TERNPhase 2
Foster City, United Statesternspharma.com

Terns Pharmaceuticals is a clinical-stage biotech focused on reimagining known biology to advance superior small-molecule therapies, primarily in oncology. The company's strategy centers on starting with de-risked, clinically validated mechanisms and innovating to accelerate the development of potentially best-in-class treatments. With a seasoned leadership team of experienced drug hunters, Terns is rapidly advancing its lead CML candidate, TERN-701, through clinical trials while maintaining a pipeline of other promising oncology programs.

Market Cap
$5.4B
+1394.3% period
Pipeline
5
drug candidates
Patents
16
granted
Publications
8
indexed

TERN · Stock Price

USD 49.61+46.29 (+1394.28%)

Historical price data

AI Company Overview

Terns Pharmaceuticals is a clinical-stage biotech focused on reimagining known biology to advance superior small-molecule therapies, primarily in oncology. The company's strategy centers on starting with de-risked, clinically validated mechanisms and innovating to accelerate the development of potentially best-in-class treatments. With a seasoned leadership team of experienced drug hunters, Terns is rapidly advancing its lead CML candidate, TERN-701, through clinical trials while maintaining a pipeline of other promising oncology programs.

Oncology

Technology Platform

A strategic development approach focused on clinically validated mechanisms of action, applying medicinal chemistry and rational drug design to create superior next-generation or best-in-class small-molecule therapies.

Pipeline

5
5 drugs in pipeline
DrugIndicationStageWatch
TERN-501 + TERN-101NASH - Nonalcoholic SteatohepatitisPhase 2
TERN-101NASH - Nonalcoholic SteatohepatitisPhase 2
TERN-601Overweight or ObesityPhase 2
TERN-701Chronic Myeloid Leukemia, Chronic PhasePhase 1/2
TERN-201NASH - Nonalcoholic SteatohepatitisPhase 1

Funding History

3
Total raised:$210M
IPO$100MFeb 11, 2021
Series B$80MJun 15, 2018
Series A$30MJun 15, 2016

Opportunities

The primary opportunity is capturing significant market share in the multi-billion dollar CML treatment market by addressing unmet needs in treatment resistance, tolerability, and treatment-free remission with TERN-701.
Success could also position Terns as an attractive partner or acquisition target.
The company's strategy allows it to pursue other large oncology indications with validated targets.

Risk Factors

Key risks include clinical failure of lead asset TERN-701, intense competition from established and novel CML therapies, financial runway constraints as a pre-revenue company, and high dependence on a single clinical program for near-term value creation.

Competitive Landscape

TERN-701 competes directly with Novartis's asciminib (Scemblix), the first approved allosteric BCR-ABL inhibitor, and other tyrosine kinase inhibitors (TKIs) like ponatinib in resistant CML. Differentiation requires demonstrating superior efficacy, safety, or convenience. The broader competitive landscape includes large pharma with deep oncology portfolios.